LC-MS/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification

[1]  J. Gottenberg,et al.  Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis , 2021, Fundamental & clinical pharmacology.

[2]  Hiromu Ito,et al.  Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS. , 2019, Journal of immunological methods.

[3]  B. Bonaz,et al.  A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease. , 2019, Analytica chimica acta.

[4]  U. Arad,et al.  Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis , 2019, The Journal of Rheumatology.

[5]  A. Yonezawa,et al.  Acceleration of nano‐surface and molecular‐orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab , 2019, Journal of pharmaceutical and biomedical analysis.

[6]  T. Naito,et al.  LC-MS/MS method for denosumab quantitation in human serum with rapid protein digestion using immobilized trypsin. , 2018, Bioanalysis.

[7]  T. Toyo’oka,et al.  Current Mass Spectrometric Tools for the Bioanalyses of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates , 2018, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[8]  J. Okamura,et al.  Simple and rapid LC‐MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin , 2017, Journal of pharmaceutical and biomedical analysis.

[9]  M. Hart,et al.  Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study , 2017, Scandinavian journal of rheumatology.

[10]  P. Sarzi-Puttini,et al.  Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab , 2016, Biologics : targets & therapy.

[11]  D. Murray,et al.  Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS. , 2015, International immunopharmacology.

[12]  Seng-Lai Tan,et al.  Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights , 2015, International reviews of immunology.

[13]  A. Murasawa,et al.  Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study , 2015, Journal of Rheumatology.

[14]  F. Regnier,et al.  Accelerating trypsin digestion: the immobilized enzyme reactor. , 2014, Bioanalysis.

[15]  O. Osilesi,et al.  Anti-inflammatory and antioxidant activities of Costus afer Ker Gawl. hexane leaf fraction in arthritic rat models. , 2014, Journal of ethnopharmacology.

[16]  Y. Saeki,et al.  Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis , 2014, Arthritis care & research.

[17]  Irene van den Broek,et al.  Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  F. Regnier,et al.  Disparities between immobilized enzyme and solution based digestion of transferrin with trypsin. , 2013, Journal of separation science.

[19]  J. Veuthey,et al.  New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: theory and applications. , 2012, Journal of pharmaceutical and biomedical analysis.

[20]  K. Hirano,et al.  Suitability of chemiluminescent enzyme immunoassay for the measurement of blood tacrolimus concentrations in rheumatoid arthritis. , 2011, Clinical biochemistry.

[21]  Yücel Şahin,et al.  Determination of oxidant stress in plasma of rheumatoid arthritis and primary osteoarthritis patients. , 2010, Indian journal of biochemistry & biophysics.

[22]  Y. Okuda.  Review of tocilizumab in the treatment of rheumatoid arthritis , 2008, Biologics : targets & therapy.

[23]  Y. Ohsugi,et al.  Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. , 2005, International immunopharmacology.

[24]  K. Abe,et al.  Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion , 2020 .